Micafungin and Anidulafungin: Dosing, Indications, and Safety
Recommended Dosing Regimens
Micafungin
For adult patients, micafungin dosing is indication-specific: 100 mg daily for candidemia and invasive candidiasis, 150 mg daily for esophageal candidiasis, and 50 mg daily for prophylaxis in hematopoietic stem cell transplant (HSCT) recipients. 1
Adult dosing:
- Candidemia, acute disseminated candidiasis, Candida peritonitis/abscesses: 100 mg IV once daily 1
- Esophageal candidiasis: 150 mg IV once daily 1
- Prophylaxis in HSCT recipients: 50 mg IV once daily 1
Pediatric dosing (≥4 months of age):
- Candidemia/invasive candidiasis: 2 mg/kg once daily (maximum 100 mg/day) 1
- Esophageal candidiasis:
- ≤30 kg: 3 mg/kg once daily
30 kg: 2.5 mg/kg once daily (maximum 150 mg/day) 1
- Prophylaxis in HSCT: 1 mg/kg once daily (maximum 50 mg/day) 1
Anidulafungin
For candidemia in adults, anidulafungin requires a 200 mg loading dose on day 1, followed by 100 mg daily maintenance dosing. 2
Adult dosing:
- Candidemia/invasive candidiasis: 200 mg loading dose, then 100 mg daily 2
- Esophageal candidiasis: Similar loading/maintenance approach 3
Treatment Duration
Treatment for candidemia should continue for 2 weeks after documented bloodstream clearance and resolution of symptoms. 2, 1 The mean treatment duration in successful cases was 15 days (range 10-47 days) for invasive candidiasis and 15 days (range 10-30 days) for esophageal candidiasis 1. For prophylaxis in HSCT recipients, the mean duration was 19 days (range 6-51 days) 1.
Clinical Indications
Guideline-Supported Uses
Echinocandins (including micafungin and anidulafungin) are strongly recommended as first-line therapy for candidemia in both neutropenic and non-neutropenic patients. 2
Primary indications:
- Candidemia and invasive candidiasis: Both agents are first-line options, particularly in critically ill patients or those with prior azole exposure 2
- Esophageal candidiasis: Effective alternatives when azoles are contraindicated 2, 1
- Prophylaxis: Micafungin specifically approved for HSCT recipients 1
Comparative Efficacy
Both agents demonstrate fungicidal activity against most Candida species, though Candida parapsilosis shows elevated MICs (1-2 μg/mL) compared to other Candida species 3. Limited data suggest anidulafungin may retain lower MICs against C. parapsilosis strains with elevated caspofungin/micafungin MICs 3. Both drugs show fungistatic activity against Aspergillus species, with micafungin and anidulafungin demonstrating 2- to 10-fold lower minimal effective concentrations than caspofungin 3.
Safety Considerations
Critical Warnings
Micafungin carries FDA warnings for hypersensitivity reactions (including anaphylaxis), hemolysis/hemolytic anemia, hepatotoxicity, and renal impairment. 1
Key safety monitoring:
Hypersensitivity reactions: Isolated cases of anaphylaxis and anaphylactoid reactions (including shock) have occurred; discontinue immediately if these develop 1
Hematological effects: Acute intravascular hemolysis and hemoglobinuria documented in healthy volunteers; monitor patients closely for hemolysis or hemolytic anemia and reassess risk/benefit if these occur 1
Hepatotoxicity: Laboratory abnormalities in liver function tests are common; isolated cases of significant hepatic impairment, hepatitis, and hepatic failure reported; monitor liver function and evaluate continuation if abnormalities develop 1
Renal effects: Elevations in BUN/creatinine and isolated cases of acute renal failure reported; monitor renal function for worsening 1
Infusion reactions: Possible histamine-mediated symptoms (rash, pruritus, facial swelling, vasodilatation); slow infusion rate if reactions occur 1
Comparative Safety Profile
Anidulafungin has the most favorable safety and drug-drug interaction profile among echinocandins, as it undergoes chemical degradation rather than hepatic metabolism. 3 This unique elimination pathway means no dose adjustment is required in hepatic or renal dysfunction 3. In contrast, micafungin undergoes hepatic metabolism via multiple pathways (arylsulfatase, COMT, CYP3A4, 1A2, 2B6, 2C), though dose adjustments are still not required in hepatic dysfunction 4.
Common adverse reactions with micafungin (≥5%): diarrhea, vomiting, hypoglycemia, hyperkalemia, increased alkaline phosphatase, and atrial fibrillation 1.
Drug-Drug Interactions
Both agents have minimal drug-drug interactions compared to azoles, as they are not significant CYP450 substrates, inhibitors, or inducers. 3 No clinically significant interaction exists between micafungin and fluconazole 5. Anidulafungin has the least potential for interactions among all echinocandins 3.
Special Populations
Critically Ill and Pediatric Patients
Critically ill patients (including burn patients) demonstrate significantly lower micafungin exposure compared to healthy volunteers, which may compromise efficacy. 4 Children show increased clearance: 40-80 mL/h/kg in premature neonates and 20 mL/h/kg in children >4 months versus 10.4 mL/h/kg in adults 4. This explains the relatively higher weight-based dosing required in pediatrics (2-4 mg/kg in children, 4-10 mg/kg in premature neonates) 4.
Therapeutic Drug Monitoring
Where available, therapeutic drug monitoring should be considered for echinocandins in high-risk populations: premature neonates, critically ill patients with altered volume of distribution or extracorporeal circuits, severe hypoalbuminemia, morbidly obese patients, and those with treatment failure. 2 A target trough concentration (Cmin) >1 mg/L is considered acceptable based on current MIC distributions and limited clinical data 2.
Administration Considerations
Micafungin must not be mixed or co-infused with other medications, as it precipitates when mixed directly with many commonly used drugs. 1 Reconstitute with 0.9% sodium chloride or 5% dextrose, then dilute in 100 mL of the same solution for adults 1. The diluted solution should be protected from light (though covering the infusion tubing is unnecessary) 1. Infusion site reactions (phlebitis, thrombophlebitis) occur more frequently with peripheral IV administration 1.
Limitations
Micafungin has not been adequately studied in endocarditis, osteomyelitis, or meningoencephalitis due to Candida, and efficacy against non-Candida fungi has not been established. 1 Both agents distribute poorly into the CNS and eye 3, limiting their utility in these infections. Tissue distribution studies show highest concentrations in liver (anidulafungin 11-66.5 μg/g, micafungin 0.36-5.53 μg/g) with lowest levels in skeletal muscle and kidneys 6.